Frontiers in Oncology (May 2024)

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma

  • Yuta Hoshi,
  • Yuta Hoshi,
  • Tomohiro Enokida,
  • Shingo Tamura,
  • Torahiko Nakashima,
  • Susumu Okano,
  • Takao Fujisawa,
  • Masanobu Sato,
  • Akihisa Wada,
  • Hideki Tanaka,
  • Naohiro Takeshita,
  • Nobukazu Tanaka,
  • Ryutaro Onaga,
  • Takuma Kishida,
  • Hideoki Uryu,
  • Shingo Sakashita,
  • Takahiro Asakage,
  • Makoto Tahara

DOI
https://doi.org/10.3389/fonc.2024.1379013
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundOlfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the recurrent or metastatic (R/M) ONB population remains unclear.MethodsWe retrospectively evaluated 11 patients with R/M ONB who received any systemic chemotherapy at two Japanese institutions (National Cancer Center Hospital East and Kyushu Medical Center) between January 2002 and March 2022 and analyzed outcomes by use of anti-PD-1 antibody (nivolumab or pembrolizumab) monotherapy.ResultsOf the 11 patients, 6 received ICI (ICI-containing treatment group) and the remaining 5 were treated with systemic therapy but not including ICI (ICI-non-containing treatment group). Overall survival (OS) was significantly longer in the ICI-containing group (median OS: not reached vs. 6.4 months, log-rank p-value: 0.035). The fraction of ICI systemic therapy in the entire treatment period of this group reached 85.9%. Four patients (66.7%) in the ICI-containing treatment group experienced immune-related adverse events (irAE), with grades of 1/2. No irAE of grade 3 or more was seen, and no patient required interruption or discontinuation of treatment due to toxicity.ConclusionICI monotherapy appears to be effective and to contribute to prolonged survival in R/M ONB.

Keywords